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Abstract
For the systemic treatment of colorectal cancer, 5-
fluorouracil (FU)–based chemotherapy is the standard.
However, only a subset of patients responds to chemo-
therapy. Breathing of carbogen (95% O2 and 5% CO2)
may increase the uptake of FU through changes in
tumor physiology. This study aims to monitor in ani-
mal models in vivo the effects of carbogen breathing on
tumor blood plasma volume, pH, and energy status,
and on FU uptake and metabolism in two colon tumor
models C38 and C26a, which differ in their vascular
structure and hypoxic status. Phosphorus-31 magnetic
resonance spectroscopy (MRS) was used to assess
tumor pH and energy status, and fluorine-19 MRS was
used to follow FU uptake and metabolism. Advanced
magnetic resonance imaging methods using ultra-
small particles of iron oxide were performed to assess
blood plasma volume. The results showed that carbo-
gen breathing significantly decreased extracellular pH
and increased tumor blood plasma volume and FU
uptake in tumors. These effects were most significant
in the C38 tumor line, which has the largest rela-
tive vascular area. In the C26a tumor line, carbogen
breathing increased tumor growth delay by FU. In this
study, carbogen breathing also enhanced systemic tox-
icity by FU.
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Introduction
Colorectal cancer is one of the most frequently occurring
cancers in the western world. For almost two decades,
5-fluorouracil (FU), in combination with leucovorin, has
been regarded as the standard adjuvant and palliative
treatment of primary colon cancer and advanced colorectal
cancer, respectively. FU is used as a radiosensitizer, in
combination with radiation therapy, of rectal cancer. Al-
though new classes of drugs have become available, FU
and other fluoropyrimidines remain part of the treatment of
colorectal cancer [1].
A critical factor in the success of the systemic treatment
of advanced colorectal cancer may be adequate drug delivery
by the vascular network to metastases. Tumor hypoxia, which
results from poor vascularization or which may even be a
constitutive characteristic of solid tumors [2,3], contributes to
drug resistance [4]. Recently, it was demonstrated that a sub-
stantial amount of hypoxia is present in liver metastases of
patients with colorectal cancer [5].
Breathing carbogen, a gas mixture of 95% O2 and 5% CO2,
has been shown to increase the uptake of anticancer drugs,
such as ifosfamide [6,7] and FU [8–10], in rodent solid tu-
mors. Carbogen breathing may induce several physiological
changes—a decrease in tumor hypoxia, an increase in tumor
blood flow, a decrease in extracellular pH (pHe), and an
increase in tumor energy status—which may all contribute to
an improved uptake of chemotherapeutic drugs. However,
these physiological changes do not occur in all experimental
tumor lines [11], and response to carbogen breathing may be
heterogeneous within a tumor [12]. In addition, it has been
hypothesized that an increase in tumor blood flow may, in itself,
be insufficient for an increased uptake of FU in solid tumors
because not only drug delivery but also drug clearance will be
increased [10]. Therefore, for carbogen to increase FU uptake,
a secondary mechanism, apart from an increase in tumor blood
flow, may be necessary.
The murine colon carcinoma lines C38 and C26a are known
as well-differentiated and poorly differentiated colon carcinoma
[13], respectively, with a differently structured vascular network
and different patterns of hypoxia, as is illustrated in Figure 1
[14]. In previous experiments, the tumor doubling time of
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untreated C26a tumors was 3 days, whereas the tumor
doubling time of untreated C38 tumors was 4.9 days [13].
C26a tumors are less responsive to FU than are C38 tu-
mors [13]. Previously, it has been shown that both C38 and
C26a tumors respond to carbogen breathing by a decrease
in tumor hypoxia [14]. Changes in other key physiological
parameters caused by carbogen breathing, which may alter
FU response, have neither been studied in these models nor
in other colon tumor models. Therefore, the aim of this study
was to monitor the effect of carbogen breathing on tumor
blood plasma volume, pH, and energy status, and on FU
uptake and metabolism in C38 and C26a colon tumors. Be-
cause these effects are monitored best in vivo, phosphorus-
31 magnetic resonance spectroscopy (MRS) was used to
assess tumor pH and energy status [15], and fluorine-19
(19F) MRS was used to follow FU uptake and metabolism
[16]. Advanced magnetic resonance imaging (MRI) methods
using ultrasmall superparamagnetic particles of iron oxide
(USPIO) were applied to study blood plasma volume [17].
The results showed that, by an increase in tumor blood
plasma volume, carbogen breathing can significantly in-
crease FU uptake and efficacy in murine colon tumors.
Materials and Methods
Tumors
The C38 and C26a murine colon tumors were acquired
from Dr. G. J. Peters of the Vrije Universiteit (Amsterdam,
The Netherlands). Viable C38 and C26a tumor tissue frag-
ments with a diameter of 1 to 3 mm were implanted sub-
cutaneously in the right flank of C57BL/6 and Balb/C mice,
respectively. Animals were kept according to institutional
guidelines for animal care. For MRS experiments, the mean
tumor volume ± standard error of the mean (SEM) calculated
from length  width  height  p/6 (mm3) was 362.2 ± 60.8
for C26a control tumors, 478.0 ± 66.5 for C26a carbogen-
treated tumors, 243.5 ± 24.4 for C38 control tumors, and
224.6 ± 49.8 for C38 carbogen-treated tumors. These tumor
volumes were not significantly different from each other,
except for the C26a carbogen-treated tumors, which had a
significantly larger tumor volume than the C38 carbogen-
treated tumors. However, no direct comparisons of MRS
data were made between C26a carbogen-treated tumors
and C38 carbogen-treated tumors. For MRI experiments, the
mean tumor volume ± SEM (mm3) was 354.8 ± 97.1 for con-
trol tumors, 320.1 ± 39.6 for C26a carbogen-treated tumors,
and 253.9 ± 23.3 for C38 carbogen-treated tumors. These
tumor volumes were not significantly different from each
other. For growth experiments, the mean tumor volume ±
SEM (mm3) was 86.6 ± 11.2 for C26a control tumors, 101.5 ±
11.7 for C26a carbogen-treated tumors, 100.7 ± 10.5 for
C38 control tumors, and 80.6 ± 4.3 for C38 carbogen-treated
tumors. These tumor volumes were not significantly different
from each other. All experiments were approved by the
institutional ethical committee for animal use.
Hardware for MR Examinations
All MR experiments were performed on an SMIS 7-T
horizontal bore animal system. A homemade 31P/19F double-
tuned 10-mm surface radiofrequency (RF) coil that was also
tunable to 1H was used as a transmitter/receiver [18]. After
mice had been anesthetized with isoflurane (1.5–2%), oxygen
(30%), and nitrous oxide (68%), the tumor was positioned at
the center of the coil. Duringmeasurements, body temperature
was monitored with a rectal fluoroptic probe (Luxtron 712;
Figure 1. Binary image of complete tumor sections of C38 (A) and C26a (B)
colon tumors showing the pattern of vascular architecture (stained with 9F1,
which is a rat monoclonal to the mouse endothelium), perfused vessels
(Hoechst33342 staining), and hypoxic profile (pimonidazole staining).
Vascular structures, red–pink; perfused vessels, blue; hypoxic areas, green.
The solid line indicates 1 mm. For further details on the immunohistochemical
methods used, refer to Van Laarhoven et al. [14].
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Luxtron Corporation, Santa Clara, CA) and maintained at
constant body temperature with a warm water pad.
31P/19F MR Measurements
A nonlocalized 31P/19F interleaved pulse-acquire se-
quence with a 90j rectangular RF pulse of 20 microseconds
was used in all experiments. Each 31P scan was alternated
with six 19F scans. The repetition time (TR) for
31P MR ac-
quisition was 3 seconds; for 19F, TR = 430 milliseconds, with
a total measurement time of 4 minutes. In total, 31 sequential
measurements were performed.
As a marker of pHe, 3-aminopropylphosphonate (3-APP;
Sigma-Aldrich, Zwijndrecht, The Netherlands) was injected
intraperitoneally through a catheter approximately 10 minutes
before the start of carbogen breathing (Figure 2A). In 10 mice
with a C38 tumor and in 12 mice with a C26a tumor, the
breathing gas was switched to carbogen 5 minutes before the
start of 31P/19F MRS measurements and was continued with
carbogen for 28 minutes (i.e., during the first seven measure-
ments). Then FU (Teva, Mijdrecht, The Netherlands) was
administered (150 mg/kg) intraperitoneally within 10 seconds
before start of the first 31P/19F MRS measurement. Twelve
mice with a C38 tumor and 10 mice with a C26a tumor did
not undergo carbogen breathing and served as controls.
MR data were processed using jMRUI, version 2.0 (http:
//www.mrui.uab.es/mrui/mruiHomePage.html). Intracellular
pH (pHi) and pHe were calculated using the chemical shift
difference between inorganic phosphate (Pi) and phospho-
creatine (PCr), and between 3-APP and PCr, respectively
[19]. The energy status of the tumor at each time point was
represented by the ratio of b-nucleoside triphosphate (bNTP)
to Pi (bNTP/Pi). Using Graphpad Prism, GraphPad Software,
Inc., San Diego, CA (version 4), quantitative changes in the
integrals of FU resonances were fitted to a biexponential
equation for each mouse, according to: Y = CFU{[1 
exp(0.693x/tuptake)]exp[0.693x/t1/2]}, where CFU refers to
the maximum concentration (a.u.) of FU, tuptake refers to the
time (minutes) up to 50% of the maximum FU resonance
amplitude in the tumor, t1/2 refers to the half-life (minutes) of
FU in the tumor, and x refers to the measurement of time
(minutes). If the data fitting this equation would not con-
verge, a monoexponential equation is used, according to:
Y = Cexp(0.693x/t1/2). Quantitative changes in the reso-
nances of anabolites, which are active metabolites of FU,
and of catabolites a-fluoro-b-ureidopropionic acid (FUPA)
and a-fluoro-b-alanine (FBAL), were fitted to a mono-
exponential equation, according to: Y = Canab,FUPA,FBAL{1 
exp[(0.693/tuptake)(x  B)]}, in which Canab,FUPA,FBAL refers
to the maximum concentration (a.u.) of the anabolite FUPA
or FBAL, and B refers to the time interval (minutes) between
the start of the measurement and the appearance of the
resonances of the anabolite FUPA or FBAL. The 19F MRS
data of individual mice were included for further calculations
and comparisons to determine if R2 z 0.8.
MRI Measurements
As a measure of relative blood plasma volume, quantita-
tive measurements of changes in the T1 relaxation rate of
Figure 2. Experimental design of MRS (A) and MRI (B) experiments (for details, see the Materials and Methods section).
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water proton spins were used after the administration of a
contrast agent consisting of USPIO [17,20].
After three gradient-echo scout MR images for anatomic
localization of the tumor, high-resolution multislice gradient-
echo images were acquired to identify one slice of interest
through the center of the tumor. Inversion recovery snap-
shot fast low-angle shot was performed to measure water T1
relaxation time [image matrix size = 64  64; field of view =
3  3 cm; slice thickness (SLT) = 1. 6 mm; TR = 5 milli-
seconds; echo time (TE) = 2. 7 milliseconds; inversion time
(TI) = 52 + n*320 milliseconds, where n = 0,1,2,. . .,15]. T1
relaxation times were measured at 1 hour after USPIO
administration at five time points (Figure 2B). The USPIO
blood pool contrast agent sinerem (150 mmol/kg Fe; Guerbet,
Roissy CDG Cedex, France) was injected intravenously
through a catheter inserted into the tail vein of all mice. In
six mice with a C38 tumor and in six mice with a C26a tumor,
carbogen breathing was started 13minutes after the injection
of sinerem (injected for 30 minutes). Three mice with a C38
tumor and four mice with a C26a tumor did not undergo
carbogen breathing and served as controls.
The Levenberg Marquardt nonlinear least squares algo-
rithm was used to analyze T1 data. The algorithm was
implemented with MatLab (Mathworks, Natick, MA). For
each tumor, voxel-by-voxel maps of apparent T1 (T1*) were
generated from a three-parameter fit of image intensities
according to the equation: S = A + Bexp(nTI/T1*). The value
of the corrected T1 was calculated from the formula: T1 = T1*
(B/A1). For each tumor,R1 (R1 = 1/T1) maps were obtained
at all time points. From each map, the mean R1 was cal-
culated by drawing a region of interest, which included the
whole tumor, on the R1 map and by averaging the values of
all pixels. The values of the mean R1 at all time points were
normalized to the value of the first time point. The mean R1
relaxation rate in controls was then compared with the mean
R1 in treated tumors, at each time point.
Tumor Growth and FU Toxicity
Separate groups of mice were followed for tumor volume
for 20 days after treatment with FU as a single treatment or in
combination with carbogen breathing, using caliper mea-
surements (control C38, n = 7; control C26, n = 8; carbogen
C38, n = 7; carbogen C26a, n = 8). To each group, four to five
mice were added to monitor systemic toxicity only. Carbogen
breathing was started 5 minutes before the intraperitoneal
administration of FU (150 mg/kg) and continued for 25 min-
utes after FU injection. Because several mice that under-
went carbogen breathing were found to be severely ill after
approximately 10 days, pathological analysis was performed
on paraffin-embedded biopsies of the heart, lungs, intes-
tines, muscles, kidneys, spleen, pancreas, and long bones,
using hematoxylin and eosin staining of the material.
Results
31P MRS Measurements
To monitor changes in pH and energy status during and
after carbogen breathing, 31P MRS was performed on C38
and C26a tumors. A typical 31P MR spectrum from a C26a
tumor is shown in Figure 3. pHi and pHe were calculated
from the chemical shift difference between the resonances
of Pi and PCr, and between 3-APP and PCr, respectively.
The energy status of the tumors was assessed by bNTP/Pi.
Table 1 summarizes the mean values of pH and the energy
status throughout measurements in the control groups of
C38 and C26a tumors. Higher pHi and pHe were found
in C38 tumors compared to C26a, but a lower DpH (DpH =
pHe pHi) was found. In both tumor lines, DpH was positive.
The bNTP/Pi energy status of C38 tumors was more than
one and a half times higher than that of C26a tumors.
The pH and energy status of C38 and C26a tumors
2 hours after the injection of FU as a single treatment or in
combination with carbogen breathing are shown in Figure 4.
In both C38 and C26a tumors, pHi remained constant
throughout the measurement. In contrast, pHe decreased
significantly in C38 tumors 15 minutes after the start of
carbogen breathing, compared with the control group, and
remained significantly lower for 32 minutes. In C26a tumors,
a similar but less pronounced pattern was observed. In C38
tumors, the decrease in pHe was large enough to result in
a decrease in DpH. The energy status of both tumor lines,
as assessed from the bNTP/Pi ratio, remained constant
throughout the experiment.
19F MRS Measurements
19F MRS was used to monitor the uptake and metabolism
of FU in C38 and C26a tumors. Figure 5 shows a typical 19F
Figure 3. 31P MR spectrum of a C26a tumor. Resonances of 3-APP as a
marker of pHe, phosphomonoesters (PME), Pi, phosphodiesters (PDE), PCr,
and high-energy phosphates (NTP) are shown. The acquisition started
12 minutes after FU injection. No carbogen breathing was applied.
Table 1. pH and Energy Status of C38 and C26a Tumors.
pHi pHe DpH bNTP/Pi
C38 7.05 ± 0.00* 7.22 ± 0.00* 0.18 ± 0.00* 2.20 ± 0.02*
C26a 6.89 ± 0.00 7.11 ± 0.00 0.22 ± 0.00 1.33 ± 0.02
Mean pH and energy status ± SEM are shown for C38 and C26a tumors from
the control groups.
*Indicates statistically significant differences between C38 and C26a tumors
(P < .001).
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MR spectrum from a C26a tumor. In most of the tumors, not
only resonance of FU but also resonances of anabolites and
of the catabolite FUPA were detected. Resonance of FBAL
was present in a minority of tumors. Due to movement
artifacts in two tumors from the C26a groups, two tumors
from the C38 control group, and one tumor from the C38
carbogen breathing group, changes in 19F MR resonance
integrals could not be fitted to a monoexponential equation
or to a biexponential equation with an R2 z 0.80. The data of
these tumors were excluded from analysis. Because the
Figure 4. pHi, pHe, DpH (pHe  pHi), and energy status (NTP/Pi) for C38 (left) and C26a (right) tumors of the control group and of the carbogen breathing group.
The error bar indicates SEM. A significant difference between the control group and the carbogen breathing group is indicated by *P < .05; ^P < 01; xP < .001.
Carbogen breathing is started at t = 5 minutes and is terminated at t = 28 minutes; FU is injected at t = 0.
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signal-to-noise ratio of the resonances of anabolites and of
the catabolite FBAL was too low to provide an adequate fit
to a monoexponential equation or to a biexponential equation
in most mice, further analyses on the pharmacokinetics of
FU and FUPA were performed.
C38 tumors had a significantly larger amount of FU and a
faster uptake of FU compared to C26a tumors (Table 2). The
half-life of FU in C38 tumors was significantly longer than in
C26a tumors, and the total amount of FU that was present in
C38 tumors (as measured by the average resonance integral
of FU) was higher. After carbogen breathing, CFU increased
in both tumor lines, but the increase was significant for C38
tumors only. In both tumor lines, tuptake decreased (i.e., FU
was taken up faster), which was significant for C26a tumors.
In both tumor lines, the average of all measured resonance
integrals in time increased on carbogen breathing, which was
significant for C38 tumors. The appearance of FUPA in C38
and C26a tumors was also monitored. In C38 tumors, the
resonance integral of FUPA increased throughout the mea-
surement period, whereas in C26a tumors, a plateau was
reached. The average of all measured resonance integrals
in time of FUPA was significantly higher in C38 tumors
(Table 3). However, the average resonance integral of FUPA
in C38 tumors divided by the average resonance integral of
FU was significantly lower that that in C26a tumors. After
carbogen breathing, the average resonance integral of FUPA
divided by the average resonance integral of FU significantly
decreased in C38 tumors compared with control tumors.
MRI Measurements
To assess the changes in blood plasma volume, the
relaxation rate R1 was determined for each tumor at five
different time points. In Figure 6, the fractional change in the
relaxation rate R1 is shown before, during, and after carbo-
gen breathing for the C38 and C26a tumors. In both tumor
lines, a significant increase in R1 was observed during car-
bogen breathing, which corresponds to an increase in tumor
blood plasma volume. The fractional increase in relative
tumor blood plasma volume during carbogen breathing was
larger in C38 tumors than in C26a tumors, which was sta-
tistically significant when taking the two time points during
carbogen breathing together (P = .03). After terminating
carbogen breathing, R1 quickly returned to control values in
C38 tumors, whereas R1 remained significantly higher in
C26a tumors than in the control group.
Tumor Growth and FU Toxicity
To determine whether carbogen breathing increased FU
efficacy, the growth of C38 and C26a tumors was mea-
sured after the administration of FU as a single agent or in
Figure 5. 19F MR spectrum of a C26a tumor. Resonances of anabolites, FU, and the catabolites FUPA and FBAL are shown. The acquisition of this spectrum
started 60 minutes after FU injection at t = 0. Carbogen breathing was applied from t = 5 minutes to t = 28 minutes.
Table 2. Pharmacokinetics of FU in C38 and C26a Tumors.
CFU (a.u.) tuptake (min) t1/2 (min) Average of All Measured
FU Resonance Integrals
in Time (a.u.)
C38 control (n = 10) 1603 ± 96.9* 0.94 ± 0.35y 72.99 ± 8.69z 929.0 ± 55.3§
C38 carbogen (n = 9) 2223 ± 85.5b 0.71 ± 0.20 65.16 ± 4.63 1223 ± 82.2#
C26a control (n = 7) 581.2 ± 37.6 2.30 ± 0.48 33.17 ± 2.56 192.9 ± 23.6
C26a carbogen (n = 10) 665.3 ± 31.3 0.54 ± 0.22** 33.00 ± 2.12 231.6 ± 31.2
The mean of the maximum concentration of FU (CFU), the doubling time of FU resonance integral increase in the tumor (tuptake), the half-life of FU in the tumor (t1/2),
and the average of all resonance integrals (average FU resonance integral) ± SEM are shown for C38 and C26a tumors. Values are calculated from a fit of the
mean resonance integral of all mice per group to a biexponential equation (see the Materials and Methods section).
*P < .0001, compared with the C26a control group.
yP < .05, compared with the C26a control group.
zP < .01, compared with the C26a control group.
§P < .0001, compared with the C26a control group.
bP < .001, compared with the C38 control group.
#P < .001, compared with the C38 control group.
**P < .01, compared with the C26a control group.
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combination with carbogen breathing. In C26a tumors, car-
bogen breathing increased FU efficacy, as is shown in Figure 7.
Approximately 10 days after the start of treatment, we
observed that, compared with the mice receiving FU only,
more mice in the groups that received FU combined with
carbogen breathing died or were severely ill (as indicated by
hair loss, shivering, and loss of mobility), and the mice were
sacrificed because of bioethical reasons. Mortality at 13 days
was significantly higher after carbogen breathing combined
with FU, compared to FU only. Pathological analysis of the
biopsies of heart muscles of ill mice showed increased
hypercontraction and eosinophilia of muscle fibers indica-
tive of acute ischemic infarction. In the bone marrow of the
long bones of diseased mice, a marked increase in mega-
karyocytes, which were also considerably variable in size,
was observed, compared with healthy mice. This may be
considered as a sign of thrombocythemia. The lungs, intes-
tines, muscles, kidneys, spleen, and pancreas did not show
abnormalities, except for pulmonary edema in one mouse.
Discussion
The key observation of this study was that carbogen breath-
ing had significant but different effects on the physiology and
FU uptake of two murine colon carcinoma lines. However,
carbogen breathing also enhanced the systemic toxicity
of FU.
A consistent effect of carbogen breathing on tumor phys-
iology in different experimental tumor lines is a decrease in
tumor hypoxia [10,11,14,21,22], although the magnitude of
this effect varied in different tumor lines [12,23]. As tumor
hypoxia may contribute to drug resistance [4], carbogen
breathing could improve the efficacy of chemotherapy. The
classic explanation for a decrease in tumor hypoxia by car-
bogen breathing is an increase in oxygen transport by blood
plasma [24]. However, several other changes in tumor
physiology have been described after carbogen breathing,
such as changes in (blood) pH, energy status, and blood
flow. These changes may not only have an impact on tumor
hypoxia but also directly influence the uptake and metabo-
lism of chemotherapeutic agents.
Changes in pH
In this study, a decrease in pHe due to carbogen breathing
was observed in C38 and C26a tumors. A similar effect has
been described in, for example, RIF-1 tumors [9], GH3
xenografts [10], and hepatomas [25]. In C38 tumors, the
decrease in pHe resulted in a decrease in DpH. Previously, it
has been shown that uptake of FU in isolated tumor cells
may be pH-dependent [15,26]. In fact, in C38 tumors, we
observed an increase in FU uptake (CFU).
Figure 6. Fractional change in the longitudinal relaxation rate R1 for C38 and C26a tumors 3 minutes before the start of carbogen breathing, during carbogen
breathing, and after the termination of carbogen breathing. *Significant difference (P < .05) between the control group and the carbogen breathing group.
**Significant difference (P < .01) between the control group and the carbogen breathing group. ¤Significant difference (P < .01) between C38 and C26a tumors. The
error bars indicate SEM.
Table 3. Uptake of FUPA in C38 and C26a Tumors.
Mean of All
Measured FUPA
Resonance
Integrals in
Time (a.u.)
Mean of the Total
FUPA Resonance
Amplitude Divided
by the Total FU
Resonance Amplitude
C38 control (n = 5) 306.2 ± 36.0* 1.1 ± 0.2y
C38 carbogen (n = 5) 278.2 ± 33.8 0.3 ± 0.1z
C26a control (n = 4) 154.6 ± 16.7 3.3 ± 0.8
C26a carbogen (n = 8) 144.2 ± 14.9 3.1 ± 0.9
The mean of the total FUPA resonance amplitude and the mean of the total
FUPA resonance amplitude divided by the total FU resonance amplitude ±
SEM are shown for C38 and C26a tumors.
*P < .001, compared with the C26a control group.
yP < .05, compared with the C26a control group.
zP < .0001, compared with the C38 carbogen group.
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It should be noted that, for 31P MRS measurements (and
19F MRS measurements), a nonlocalized acquisition tech-
nique was used to obtain sufficient time resolution. This
implies that some contributions (<30%) from muscles and
the skin will be present.
Energy Status
The pretreatment energy status (NTP/Pi) of chemically
induced primary rat mammary tumors has been shown to
be a predictor of tumor response [27,28]. It has been hy-
pothesized that an elevated energy status may reflect a
well-vascularized tumor, which has more capacity for energy-
dependent FU uptake and anabolism [27]. In this study, a
large difference in energy status was observed between
C38 and C26a tumors, with relatively high values for C38
tumors. Previously, it has been shown that the tumor energy
status decreased when mean intercapillary distance in-
creased (i.e., tumor perfusion decreased) [29]. As the C38
tumor is a well-perfused tumor [14], this could explain the
relatively higher levels of NTP/Pi in C38 than in C26a tumors.
The large difference in energy status between C38 and
C26a tumors corresponds well to the difference in relative
blood plasma volume [17] and relative vascular area [14] in
these tumor lines, as well as to the difference in chemo-
therapy sensitivity [13].
In subcutaneous hepatomas, an increase in NTP/Pi was
observed during carbogen breathing, whereas energy sta-
tus in GH3 xenografts remained constant [10]. For human
gliomas implanted subcutaneously in mice, a decrease in
energy status on carbogen breathing has been observed
[11], which was likely due to the so-called steal effect (as
described by Jirtle [30]; see below). In subcutaneous
C38 and C26a tumors, no difference in energy status be-
tween the control group and the carbogen breathing group
was observed.
Blood Plasma Volume
In the slower-growing C38 tumors, compared to the
faster-growing C26a tumors, a larger blood plasma volume
[17] and a relative vascular area have been observed [14].
This could explain the higher maximum concentration of
FU and the higher average resonance integral of FU and
FUPA in C38 tumors. The higher maximum concentration
and the average resonance integral of FU in C38 tumors, as
well as the longer half-life of FU, may contribute to the higher
chemosensitivity of C38 tumors compared to C26a tumors,
which has been described before [13].
The effects of carbogen on the tumor vasculature are
usually measured in terms of tumor blood flow and/or vascu-
lar diameter. O2 has been shown to have a vasoconstrictive
Figure 7. Growth curves of C38 (A) and C26a tumors (B) after the administration of FU (150 mg/kg) as a single treatment or in combination with carbogen
breathing. Tumor volumes are normalized to 1 on day 0, which is the day of treatment. Error bars indicate SEM. *Significant difference (P < .05) between the control
group and the carbogen breathing group. **Significant difference (P < .01) between the control group and the carbogen breathing group.
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effect on both immature and mature tumor vessels [31].
In theory, the CO2 component of carbogen (95% O2 and
5% CO2) may overcome the vasoconstrictive effects of
O2. However, in this respect, variable effects of carbogen
breathing have been reported. In subcutaneously or intra-
muscularly implanted R3230Ac tumors, carbogen had no
consistent effect on tumor blood flow measured by Doppler
flowmetry [23]. In another study with the same tumor model,
carbogen breathing resulted in a transient reduction in tumor
arteriolar diameter measured by intravital microscopy and
a reduction in tumor blood flow measured by Doppler flow-
metry [32]. In subcutaneous human glioblastomas, a de-
crease in tumor blood flow after carbogen breathing was
observed by fast dynamic 1H MRI of Gd-DTPA uptake [11],
possibly due to a steal effect [30]. The steal effect refers to a
situation wherein the tumor vasculature lacks a responsive
smooth musculature and is in parallel with the host vascula-
ture. Tumor blood perfusion could then be reduced during
carbogen breathing due to a vasodilating effect of the CO2
component of carbogen on host vessels. In this study, tumor
blood plasma volume was assessed using MRmethods, with
ultrasmall superparamagnetic iron oxide as a contrast agent.
In both C38 and C26a tumors, a significant increase was
observed in the relaxation rate R1, which is proportional to an
increase in relative tumor blood plasma volume. Therefore,
these results suggest a vasodilating effect of carbogen
breathing, rather than a vasoconstrictive or steal effect, in
C38 and C26a tumors. This is the first study to show an in-
creased relative tumor blood plasma volume after carbogen
breathing using this MR approach. The advantage of this
technique, in contrast with measurements of vascular diame-
ter, is that it could be applied not only in subcutaneous
(window chamber) models but also in orthotopic models.
Moreover, the interpretation of data for this study is more
straightforward than, for example, that for blood oxygena-
tion–dependent MRI measurements, which reflect a combi-
nation of blood oxygenation, flow, and volume responses [33].
Because MRI techniques using blood pool agents mea-
sure the volume of plasma-perfused vessels and do not
account for hematocrit (i.e., potential oxygen-carrying eryth-
rocytes), they may overestimate oxygen delivery [33]. For
the delivery of chemotherapy, plasma-perfused vascular vol-
ume rather than vascular volume occupied by erythrocytes
is of primary importance, although tumor hypoxia may be
related to chemotherapy resistance [34]. The observed in-
crease in relative tumor blood plasma volume after carbogen
breathing implies that the vascular surface area in the tumor
is increased, which could lead to an improved tumor uptake
of FU. In both C38 and C26a tumors, CFU and the average of
all measured FU resonance integrals in time were increased
in the carbogen breathing group compared to those in the
control group, although this was significant for C38 tumors
only. In fact, blood plasma volume response to carbogen
breathing was also larger in C38 tumors than in C26a tumors.
Previously, similar 19F MRS results were reported for C38
tumors when carbogen breathing was initiated 1 minute be-
fore and maintained 8.5 minutes after FU (150 mg/kg) bolus
injection [8]. In that study, increased levels of FU, as well as
increased levels of anabolites and catabolites, without en-
hanced FU retention in the tumor were found. In the present
study, after terminating carbogen breathing, the relative blood
plasma volume in C38 tumors returned to control values
more quickly than the relative blood plasma volume in C26a
tumors. This indicates a difference in responsive tumor
vasculature in C38 and C26a tumors. In fact, on a micro-
scopic level, the tumor vasculature of C38 and C26a tumors
is rather different: C38 tumors mainly show large vessels in a
corded structure, whereas in C26a tumors, the tumor vascu-
lature consists of smaller vessels [14].
Tumor Growth and Toxicity
Although the effects of carbogen breathing on tumor
physiology and FU pharmacokinetics are stronger in C38
tumors than in C26a tumors, the direction of changes in
both tumor lines favors an increased efficacy of FU when
combined with carbogen breathing. The fact that C26a tu-
mors profit more from carbogen breathing than do C38
tumors could be explained by their different tumor micro-
environment. At the same tumor size, C26a tumors are less
well vascularized than C38 tumors [14]. Previously, it has
been shown by McSheehy et al. [9] that larger, presumably
less-vascularized RIF-1 tumors profit more from carbogen
breathing in terms of cytotoxic treatment efficacy than
smaller, better-vascularized tumors.
It should be noted that, at the dose of FU used in the MRS
experiments (150 mg/kg), enhanced toxicity and early
deaths were observed in the group that underwent carbogen
breathing. This is the first report of carbogen-induced toxicity,
in combination with FU therapy. In patients, cardiac toxicity
has been observed after continuous high-dose infusion of FU
[35], and megakaryocytosis is a well-described effect of FU
on the bone marrow [36]. Thus, pathological anatomic ob-
servations in this experiment (ischemic necrosis of the
heart muscles, cardiac failure, and thrombocytosis) may
be related to FU-induced systemic toxicity, and high levels
of catabolites have been associated with cardiotoxicity
[37–39]. In this study, no increase in catabolite levels in
the group of mice that underwent carbogen breathing was
observed. However, because catabolites are mainly pro-
duced in the liver and are taken up in the tumor through
the blood circulation [40–43], the level of catabolites in the
tumor is not necessarily correlated with catabolite levels in
other organs, such as heart muscles.
In previous studies, no toxicity has been described after
the combination of FU treatment with carbogen breathing. In
fact, Griffiths et al. [44] showed that there were no significant
effects of carbogen breathing on the levels of FU and its
metabolites in normal rat tissues, and on the histology of
tissues. In that study, FU was administered at a dose of
50 mg/kg, and carbogen was applied for a shorter time
(10 minutes). Not only the administered dose of FU but also
the duration of carbogen breathing may be crucial for the
occurrence of systemic toxicity. In a recent study, increased
clearance of FU from the plasma was observed after 30 min-
utes of carbogen breathing compared to 20 minutes of
carbogen breathing [10]. If this increased clearance of FU
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is caused by an increased uptake of FU in vital organs
such as the heart muscles, this may well explain the ob-
served toxicity.
In conclusion, these results show that, even within one
tumor type, namely, colon carcinoma, the effects of carbogen
breathing on tumor physiology and FU uptake and metabo-
lism differ, which may be caused by differences in tumor
vasculature. For clinical applications, this underscores the
importance of an early analysis of response to carbogen
breathing (e.g., by 19F MRS) in individual patients. In the
murine models C38 and C26a, an increase in FU uptake in
the tumors was observed after carbogen breathing and FU
efficacy in C26a tumors had increased. Because systemic
toxicity was also enhanced, a clinical study evaluating the
effect of carbogen breathing on FU efficacy should be
preceded by a phase I trial monitoring the effect of carbogen
breathing on FU toxicity.
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